Please note that we have stopped the regular imports of Gene Expression Omnibus (GEO) data into ArrayExpress. This may not be the latest version of this experiment.

E-GEOD-43526 - Co-ordinate inhibition of autism candidate genes by topoisomerase inhibitors [Seq]

Released on 30 August 2013, last updated on 24 October 2013
Homo sapiens, Mus musculus
Samples (14)
Protocols (9)
Topoisomerases are necessary for the expression of neurodevelopmental genes, and are mutated in some patients with autism spectrum disorder (ASD). We have studied the effects of inhibitors of Topoisomerase 1 (Top1) and Topoisomerase 2 (Top2) enzymes on mouse cortical neurons. We find that topoisomerases selectively inhibit long genes (>100kb), with little effect on all other gene expression. Using ChIPseq against RNA Polymerase II (Pol2) we show that the Top1 inhibitor topotecan blocks transcriptional elongation of long genes specifically. Many of the genes inhibited by topotecan are candidate ASD genes, leading us to propose that topoisomerase inhibition might contribute to ASD pathology. [Mouse] 5 biological replicates of transcriptome sequencing (RNAseq) from topotecan treated neurons and vehicle treated controls; Pol2 ChIPseq of topotecan and vehicle treated neurons [Human] Transcriptome sequencing (RNAseq) from topotecan treated neurons and vehicle treated control.
Experiment types
ChIP-seq, RNA-seq of coding RNA 
Topoisomerases facilitate transcription of long genes linked to autism. King IF, Yandava CN, Mabb AM, Hsiao JS, Huang HS, Pearson BL, Calabrese JM, Starmer J, Parker JS, Magnuson T, Chamberlain SJ, Philpot BD, Zylka MJ. , PMID:23995680
Exp. designProtocolsVariablesProcessedSeq. reads
Investigation descriptionE-GEOD-43526.idf.txt
Sample and data relationshipE-GEOD-43526.sdrf.txt
Processed data (1)